Theresa M. Williams
Theresa M. Williams has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Amy G. Quigley
Department of Medicinal Chemistry Merck & Co., West Point, PA 19486, USA
1 shared publicationBang-Lin Wan
Department of Medicinal Chemistry Merck & Co., West Point, PA 19486, USA
1 shared publicationC. Blair Zartman
Department of Medicinal Chemistry Merck & Co., West Point, PA 19486, USA
1 shared publicationChristopher Salvatore
Department of Pain Research, Merck & Co., West Point, PA 19486, USA
1 shared publicationCraig A. Stump
Department of Medicinal Chemistry Merck & Co., West Point, PA 19486, USA
1 shared publicationDiem N. Nguyen
Department of Medicinal Chemistry Merck & Co., West Point, PA 19486, USA
1 shared publication
Latest Publications
- 1 May 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (10) , 2595-2598
Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead
- 1 May 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (10) , 2595-2598
Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead
- 1 September 1999
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (9) , 1263-1280
Inhibitors of protein prenylation 1999
Interest in farnesyltransferase inhibitors (FTIs) as a potential cancer therapy continues, judging from the approximately eighty patent applications published in the fourteen month period from January 1998. This review summarises progress in the field since the previous update [1] and includes a description of the first clinical trials in man. Also discussed are current biological experiments designed to further understand the preclinical antiproliferative effects of FTIs. Recent structural studies of farnesyltransferase (FTase) are summarised. Novel FTIs appearing in the scientific and patent literature in the past year are reviewed, along with new data published on key compounds, such as those undergoing clinical evaluation.
- 1 September 1999
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (9) , 1263-1280
Inhibitors of protein prenylation 1999
Interest in farnesyltransferase inhibitors (FTIs) as a potential cancer therapy continues, judging from the approximately eighty patent applications published in the fourteen month period from January 1998. This review summarises progress in the field since the previous update [1] and includes a description of the first clinical trials in man. Also discussed are current biological experiments designed to further understand the preclinical antiproliferative effects of FTIs. Recent structural studies of farnesyltransferase (FTase) are summarised. Novel FTIs appearing in the scientific and patent literature in the past year are reviewed, along with new data published on key compounds, such as those undergoing clinical evaluation.